Featured Content

Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer

Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.

BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors

Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Identifying Gene Variants Involved in Radiotherapy Toxicity Risk: A Q&A With Benjamin Smith, MD

Genomics could guide the decision about whether a patient should undergo implant reconstruction or autologous tissue-based reconstruction.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

More Features>>>

Breast Cancer Resources

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs